Javascript must be enabled to continue!
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
View through CrossRef
Abstract
Background
Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there was little previous study that demonstrate the IBD severity and outcome in IBD patients with concomitant AS.
Methods
Patients’ records were collected from 3 tertiary hospitals (Seoul national university hospital, Seoul national university Bundang hospital, and Seoul metropolitan government Seoul national university Boramae medical center) from October 2004 to June 2021. Patients with IBD and concomitant AS (IBD-AS group) were identified and propensity score matching (PSM) was applied to match the IBD-AS group and IBD patients without AS (only IBD group).
Results
After PSM, significantly more patients in IBD-AS group had colectomies (p = .017) or were prescribed biologics (p < .001), immunosuppressive agents (p = .021), and steroid (p = .017) than in only IBD group. The number of patients treated with biologics (p < .001) or immunosuppressive agents (p = .032) were significantly greater in UC-AS group than in only UC group. There was no significant difference in outcomes between only CD group and CD-AS group. In logistic regression analyses, identified that concomitant AS was a significant factor associated with biologics treatment in patients with IBD. Kaplan-Meier analyses demonstrated that there was a significant difference in the probability of starting biologics treatment between IBD patients with and without concomitant AS (p = 0.002). In UC patients, the probability of starting biologics was also significantly different according to concomitance of AS (p < 0.001). Concomitant AS was a risk factor for predicting biologics treatment in patients with UC in Cox regression analysis after adjustment UC (adjusted hazard ratio, 6.296; confidence interval, 2.243 to 17.668; p < 0.001)
Conclusion
Patients with IBD-AS group were more likely to have a higher severity than in only IBD group. The current study result can help IBD specialists understand and treat patients with IBD and concomitant AS better.
Title: P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
Description:
Abstract
Background
Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there was little previous study that demonstrate the IBD severity and outcome in IBD patients with concomitant AS.
Methods
Patients’ records were collected from 3 tertiary hospitals (Seoul national university hospital, Seoul national university Bundang hospital, and Seoul metropolitan government Seoul national university Boramae medical center) from October 2004 to June 2021.
Patients with IBD and concomitant AS (IBD-AS group) were identified and propensity score matching (PSM) was applied to match the IBD-AS group and IBD patients without AS (only IBD group).
Results
After PSM, significantly more patients in IBD-AS group had colectomies (p = .
017) or were prescribed biologics (p < .
001), immunosuppressive agents (p = .
021), and steroid (p = .
017) than in only IBD group.
The number of patients treated with biologics (p < .
001) or immunosuppressive agents (p = .
032) were significantly greater in UC-AS group than in only UC group.
There was no significant difference in outcomes between only CD group and CD-AS group.
In logistic regression analyses, identified that concomitant AS was a significant factor associated with biologics treatment in patients with IBD.
Kaplan-Meier analyses demonstrated that there was a significant difference in the probability of starting biologics treatment between IBD patients with and without concomitant AS (p = 0.
002).
In UC patients, the probability of starting biologics was also significantly different according to concomitance of AS (p < 0.
001).
Concomitant AS was a risk factor for predicting biologics treatment in patients with UC in Cox regression analysis after adjustment UC (adjusted hazard ratio, 6.
296; confidence interval, 2.
243 to 17.
668; p < 0.
001)
Conclusion
Patients with IBD-AS group were more likely to have a higher severity than in only IBD group.
The current study result can help IBD specialists understand and treat patients with IBD and concomitant AS better.
Related Results
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily sacroiliac joints and the spine. It is a gradually progressive condition over severa...
Reproductive health in women with ankylosing spondylitis: contraception and fertility. A narrative review
Reproductive health in women with ankylosing spondylitis: contraception and fertility. A narrative review
Objective. The knowledge of ankylosing spondylitis is rising, and more and more attention is being paid to the diagnosis of this pathology in females. The purpose of this narrative...
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
AbstractAim:Childhood onset inflammatory bowel disease is more aggressive and has rapidly progressive clinical course than adult inflammatory bowel disease. Early-onset inflammator...
Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis
Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis
Objectives: This study aims to determine the levels of bone turnover markers in canonical wingless pathway in patients with ankylosing spondylitis (AS) and the correlation with dis...
Safety and Clinical Response in Ankylosing Spondylitis after Three Months of Etanercept Therapy
Safety and Clinical Response in Ankylosing Spondylitis after Three Months of Etanercept Therapy
Abstract
Objective: To look for safety and clinical response in ankylosing spondylitis after three months of Etanercept therapy and factors associated with response.
Study Design: ...
Early signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis
Early signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis
The objective of the study – identify early preclinical signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis.Material and methods. We ex...
Primary Biliary Cirrhosis and Ankylosing Spondylitis, A Rare Association
Primary Biliary Cirrhosis and Ankylosing Spondylitis, A Rare Association
Abstract
Primary biliary cirrhosis is an autoimmune liver disease, characterized by the progressive destruction of the small intrahepatic bile duct epithelial cells ...
Frequency of extra articular manifestations in ankylosing spondylitis patients presented at independent university hospital Faisalabad.
Frequency of extra articular manifestations in ankylosing spondylitis patients presented at independent university hospital Faisalabad.
Objective: To determine the frequency of extra articular manifestations in Ankylosing spondylitis patients at Independent University Hospital Faisalabad. Study Design: Cross-sectio...

